Evidence explorer

Every claim we hold, and how far we can stand behind it.

142 claims across 39 products. 30% are confirmed against the source text by the evidence gate; 39% come from a class with no vendor interest. Everything below is browsable, filterable, and available as JSON.

What this corpus is made of

Evidence class	Claims	Confirmed	What it can support
Peer-reviewed study	19	5	Independent review before publication. The only class that survives a sceptical committee unaided.
Regulatory filing	4	0	A statement made to a regulator, where being wrong has consequences.
Independent report	32	9	Analysis by someone with no stake in the sale.
Customer case	4	3	A real deployment, but selected and framed by someone with an interest.
Press release	63	23	The vendor's own announcement. Useful for dates and facts, not for outcomes.
Vendor page	20	2	Marketing copy. Establishes what is claimed, never that it is true.

Showing 3 of 3 matching claims (142 in the full corpus) · 0% of this selection is confirmed · clear filters

Real-world performance evaluation of the Aidoc Medical Briefcase ICH Triage model across 101,944 non-contrast head CT examinations from 74,142 patients in a 17-facility academic health system (April 2023-April 2025) demonstrated 82.2% sensitivity, 97.6% specificity, and 96.6% accuracy for intracranial hemorrhage detection (npj Digital Medicine).
Aidoc aiOSPeer-reviewed studyUnverified2025-12-24Open source ↗
Provenance
Claim ID
clm_c0fa19558e3ea5d6059f
Version
1
Workflow
Imaging & Diagnostic AI
Dimension
evidence strength
Retrieved
2026-08-27
Reviewer
healthit-gate-v1
Source URL
https://pmc.ncbi.nlm.nih.gov/articles/PMC12823562/
Meta-analysis of six retrospective real-world studies encompassing 9,102 CTPA scans, all assessing the Aidoc or CINA-PE FDA-approved algorithms for acute pulmonary embolism detection, found pooled sensitivity of 93% (95% CI 88%-95%) and specificity of 98% (95% CI 93%-100%) (Cureus).
Aidoc aiOSPeer-reviewed studyUnverified2025-10-01Open source ↗
Provenance
Claim ID
clm_15d57030cdd4dbabf213
Version
1
Workflow
Imaging & Diagnostic AI
Dimension
evidence strength
Retrieved
2026-08-27
Reviewer
healthit-gate-v1
Source URL
https://pmc.ncbi.nlm.nih.gov/articles/PMC12604435/
CEO Prashant Warier states Qure.ai aims to reach profitability in the next financial year and pursue an IPO within roughly two years (May 2025)
qXR (Chest X-ray AI Suite)Press releaseUnverified2025-05-20Open source ↗
Provenance
Claim ID
clm_feb6e7535e4e9cab9d13
Version
1
Workflow
Imaging & Diagnostic AI
Dimension
market durability
Retrieved
2026-08-27
Reviewer
healthit-gate-v1
Source URL
https://m.economictimes.com/tech/artificial-intelligence/healthcare-ai-startup-qure-ai-aiming-for-ipo-in-two-years-ceo-says/articleshow/121286035.cms

Know a source we are missing?